


March 9, 2004



Micheline Gravelle B.Sc., M.Sc. (Immunology)
416 957 1682 mgravelle@bereskinparr.com

Your Reference: 10/731,741
Our Reference: 2223-171

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450
U.S.A

Dear Sirs:

Re: Filing of an Information Disclosure Statement
U.S. Patent Application No. 10/731,741
Entitled: Cell Preparations Comprising Cells of the T Cell Lineage and
Methods of Making and Using Them
Filed: December 10, 2003
Applicants: Thomas M. Schmitt and Juan Carlos Zuniga-Pflucker
Group Art No.: Unknown

In accordance with 37 CFR 1.97 and 1.98, and in recognition of the duty of disclosure set forth in 37 CFR 1.56, Applicants hereby submit an Information Disclosure Statement on Form PTO/SB/08a containing a listing of patents and other publications of which Applicant is aware. Applicants are also submitting the references listed on the Information Disclosure Statement.

All of the patents and publications submitted herewith are in the English language. Accordingly a concise explanation of the relevance of the documents is not required.

The Examiner is requested to indicate consideration of these documents by initialling the appropriate column.

Applicants reserve the right to contest the applicability of any of these documents as prior art against the subject application. If the Examiner has any questions concerning this Information Disclosure Statement, he/she is requested to contact the undersigned. Entry of the enclosed Information Disclosure Statement is believed to be in order and is respectfully requested.

Please send all correspondence to the Toronto office:

Scotia Plaza, 40 King St. West, 40th Floor,
Toronto, Ontario, Canada M5H 3Y2
Tel: 416.364.7311 Fax: 416.361.1398

2000 Argentia Rd., Plaza 4, Ste. 430,
Mississauga, Ontario, Canada L5N 1W1
Tel: 905.812.3600 Fax: 905.814.0031

Waterloo Technology Campus, 408 Albert St., Ste. 2,
Waterloo, Ontario, Canada N2L 3V3
Tel: 519.783.3210 Fax: 519.783.3211

This Information Disclosure Statement is being filed before the issuance of a first official action, and therefore no fees are required. However, please charge our deposit account No. 02-2095 if such a fee is required.


Respectfully submitted,

**Thomas M. Schmitt and
Juan Carlos Zuniga-Pflucker**

A handwritten signature in black ink, appearing to read "M. Gravelle", written over a horizontal line.

Micheline Gravelle
Registration No. 40,261

MG/jl
Encl.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number

10/731,741

Filing Date

December 10, 2003

First Named Inventor

Thomas M. Schmitt et al.

Group Art Unit

Unknown

Examiner Name

Unknown

Attorney Docket Number

2223-171

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Schmitt et al. 2002. Induction of T Cell Development from Hematopoietic Progenitor Cells by Delta-like-1 In Vitro. Immunity, Vol 17, 749-756.	
	2	Lehar and Bevan 2002. T Cell Development in Culture. Immunity Vol 17, 689-692.	
	3	Nakano et al 1994. Generation of Lymphohematopoietic Cells from Embryonic Stem Cells in Culture. Science, Vol 265, 1098-1101.	
	4	Hare et al 1999. In vitro models of T cell development. Semin Immunol 11(1), 3-12.	
	5	Dorsch et al 2002. Ectopic expression of Delta4 impairs hematopoietic development and leads to lymphoproliferative disease. Blood Vol 100(6), 2046-55.	
	6	Mailhos et al 2001. Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation Vol 69(2-3) 135-44.	
	7	Eto et al 2002. Megakaryocytes derived from embryonic stem cells implicate CalDAG-GEFI in integrin signaling. Proc Natl Acad Sci. Vol 99 (20), 12819-24.	
	8	Artavanis-Tsakonas et al 1999. Notch Signaling: Cell Fate Control and Signal Integration in Development. Science Vol 28, 770-776.	
	9		
	10		
	11		

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.